NFKB1 and atherosclerosis: Since inflammation-driven endothelial dysfunction is a prime trigger in atherosclerosis initiation and exacerbation, compounds that attenuate TNF-α- induced NF-κB activation and subsequent expression of inflammatory markers are potential therapies to vascular endothelial dysfunction.